TNGX

Neutral

Assessing Tango Therapeutics (TNGX) Valuation After Trial Progress And Leadership Changes

Tango Therapeutics (TNGX) recently reported a net loss of US$45.51m for the first quarter, alongside clinical progress updates and executive changes. ...

Simply Wall Street 6 days ago 0

Neutral

Assessing Tango Therapeutics (TNGX) Valuation After Leadership Changes And New Pan RAS Supply Agreement

Tango Therapeutics (TNGX) has experienced significant stock volatility following leadership changes, a new supply agreement for pan RAS, and pipeline ...

Simply Wall Street 2 weeks ago 0

Neutral

Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation

Tango Therapeutics director Lee Sung received 12,300 restricted stock units (RSUs) and an option for 5,200 shares as part of his board compensation. T...

Stock Titan 2 weeks ago 0